Liisa Bayko
Stock Analyst at Evercore ISI Group
(3.30)
# 433
Out of 4,479 analysts
65
Total ratings
48.98%
Success rate
2.12%
Average return
Main Sectors:
Top Industries:
23 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $210 → $260 | $243.32 | +6.86% | 1 | Jun 25, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: In-Line | $27 → $2 | $1.70 | +17.65% | 2 | Jun 18, 2024 | |
| EDIT Editas Medicine | Maintains: In-Line | $15 → $7 | $4.61 | +51.84% | 2 | May 30, 2024 | |
| ANTX AN2 Therapeutics | Maintains: In-Line | $7 → $2 | $2.13 | -6.10% | 3 | May 16, 2024 | |
| ETNB 89bio | Maintains: Outperform | $37 → $33 | $7.76 | +325.26% | 4 | May 15, 2024 | |
| AKRO Akero Therapeutics | Maintains: Outperform | $50 → $38 | $23.16 | +64.08% | 3 | May 15, 2024 | |
| KNSA Kiniksa Pharmaceuticals | Maintains: Outperform | $25 → $30 | $18.67 | +60.69% | 2 | Apr 24, 2024 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | $438 | $471.25 | -7.06% | 13 | Apr 11, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $325 → $405 | $279.31 | +45.00% | 8 | Mar 20, 2024 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $30 → $14 | $8.28 | +69.08% | 4 | Sep 22, 2023 | |
| CARM Carisma Therapeutics | Initiates: Outperform | $12 | $1.67 | +618.56% | 1 | Jul 6, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $60 → $80 | $41.12 | +94.55% | 5 | Jun 6, 2023 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $13 → $10 | $6.67 | +49.93% | 4 | Apr 20, 2023 | |
| ATXS Astria Therapeutics | Initiates: Outperform | $18 | $9.25 | +94.59% | 1 | Mar 28, 2023 | |
| ALT Altimmune | Maintains: Outperform | $14 → $25 | $7.20 | +247.22% | 1 | Jan 18, 2023 | |
| ENTA Enanta Pharmaceuticals | Upgrades: Outperform | $62 | $13.07 | +374.37% | 4 | Jul 6, 2022 | |
| CRSP CRISPR Therapeutics AG | Downgrades: In-Line | $66 → $60 | $53.95 | +11.21% | 1 | Jun 23, 2022 | |
| AURA Aura Biosciences | Initiates: Outperform | n/a | $7.37 | - | 1 | Nov 23, 2021 | |
| VERA Vera Therapeutics | Initiates: Outperform | n/a | $36.29 | - | 1 | Jun 8, 2021 | |
| TBIO Telesis Bio | Downgrades: In-Line | $378 | $3.86 | +9,692.75% | 1 | Mar 18, 2021 | |
| TBPH Theravance Biopharma | Reinstates: Outperform | n/a | $8.52 | - | 1 | Nov 24, 2020 | |
| ABUS Arbutus Biopharma | Upgrades: Market Outperform | n/a | $3.12 | - | 1 | Feb 5, 2020 | |
| SVRA Savara | Initiates: Market Outperform | n/a | $4.64 | - | 1 | Sep 11, 2017 |
Alnylam Pharmaceuticals
Jun 25, 2024
Maintains: Outperform
Price Target: $210 → $260
Current: $243.32
Upside: +6.86%
Aerovate Therapeutics
Jun 18, 2024
Downgrades: In-Line
Price Target: $27 → $2
Current: $1.70
Upside: +17.65%
Editas Medicine
May 30, 2024
Maintains: In-Line
Price Target: $15 → $7
Current: $4.61
Upside: +51.84%
AN2 Therapeutics
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $2.13
Upside: -6.10%
89bio
May 15, 2024
Maintains: Outperform
Price Target: $37 → $33
Current: $7.76
Upside: +325.26%
Akero Therapeutics
May 15, 2024
Maintains: Outperform
Price Target: $50 → $38
Current: $23.16
Upside: +64.08%
Kiniksa Pharmaceuticals
Apr 24, 2024
Maintains: Outperform
Price Target: $25 → $30
Current: $18.67
Upside: +60.69%
Vertex Pharmaceuticals
Apr 11, 2024
Upgrades: Outperform
Price Target: $438
Current: $471.25
Upside: -7.06%
Madrigal Pharmaceuticals
Mar 20, 2024
Maintains: Outperform
Price Target: $325 → $405
Current: $279.31
Upside: +45.00%
Travere Therapeutics
Sep 22, 2023
Maintains: Outperform
Price Target: $30 → $14
Current: $8.28
Upside: +69.08%
Carisma Therapeutics
Jul 6, 2023
Initiates: Outperform
Price Target: $12
Current: $1.67
Upside: +618.56%
Ultragenyx Pharmaceutical
Jun 6, 2023
Upgrades: Outperform
Price Target: $60 → $80
Current: $41.12
Upside: +94.55%
BioCryst Pharmaceuticals
Apr 20, 2023
Maintains: Outperform
Price Target: $13 → $10
Current: $6.67
Upside: +49.93%
Astria Therapeutics
Mar 28, 2023
Initiates: Outperform
Price Target: $18
Current: $9.25
Upside: +94.59%
Altimmune
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $7.20
Upside: +247.22%
Enanta Pharmaceuticals
Jul 6, 2022
Upgrades: Outperform
Price Target: $62
Current: $13.07
Upside: +374.37%
CRISPR Therapeutics AG
Jun 23, 2022
Downgrades: In-Line
Price Target: $66 → $60
Current: $53.95
Upside: +11.21%
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.37
Upside: -
Vera Therapeutics
Jun 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $36.29
Upside: -
Telesis Bio
Mar 18, 2021
Downgrades: In-Line
Price Target: $378
Current: $3.86
Upside: +9,692.75%
Theravance Biopharma
Nov 24, 2020
Reinstates: Outperform
Price Target: n/a
Current: $8.52
Upside: -
Arbutus Biopharma
Feb 5, 2020
Upgrades: Market Outperform
Price Target: n/a
Current: $3.12
Upside: -
Savara
Sep 11, 2017
Initiates: Market Outperform
Price Target: n/a
Current: $4.64
Upside: -